Literature DB >> 16610054

Construction and evaluation of anti-gastrin immunogen based on P64K protein.

Xiang-Hua Xiong1, Hong-Liang Zhao, Chong Xue, Wei Zhang, Bing-Fen Yang, Xue-Qin Yao, Zhi-Min Liu.   

Abstract

AIM: To construct two kinds of anti-gastrin immunogen based on P64K protein from Neisseria meningitids and to compare their immunogenic effect.
METHODS: G17P64K gene was cloned and ligated into pET28a plasmid, then transformed into BL21(DE3). After inoculation of LB medium and IPTG induction, the recombinant protein was solubly expressed at a high level. The purification of G17P64K fusion protein was similar to that of P64K. An initial step of purification consisting of 30% saturated ammonium sulfate precipitation was done. Additional fine optimizations included phenyl-sepharose, G200 Sephadex gel filtration and Q-sepharose anion exchanger chromatography. Highly purified protein was obtained and sequenced at the N-terminal amino acid residues. Polypeptide was synthesized by Fmoc solid phase chemical method and cross-linked to carrier protein P64K and DT mutant by MBS method and then the rabbit anti-gastrin 17 antibody was prepared by immunizing rabbit with cross-linked and fused protein. The titer and the activity in vitro of antibody were assessed.
RESULTS: G17P64K gene and the recombinant bacteria were obtained. After four steps purification, protein sample that has the purity above 90% was achieved. At the 84(th) day after the first immunization, the titer of antibody against cross-linked protein reached 51,200. Evaluation of the antibody in vitro manifested that it had a high inhibitory activity on the growth of tumor cell SW480.
CONCLUSION: The P64K-polypeptide cross-linked immunogen immunized rabbit and achieved a higher titer antibody against gastrin 17 than the G17P64K fusion protein immunogen, which could inhibit the growth of the tumor cell SW480.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16610054      PMCID: PMC4087682          DOI: 10.3748/wjg.v12.i13.2040

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

Review 1.  Signal transduction and activation of acid secretion in the parietal cell.

Authors:  T Urushidani; J G Forte
Journal:  J Membr Biol       Date:  1997-09-15       Impact factor: 1.843

2.  Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer.

Authors:  A M Smith; T Justin; D Michaeli; S A Watson
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

3.  Structure of a human gastrin gene.

Authors:  O Wiborg; L Berglund; E Boel; F Norris; K Norris; J F Rehfeld; K A Marcker; J Vuust
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

4.  Carrier-priming leads to hapten-specific suppression.

Authors:  L A Herzenberg; T Tokuhisa; L A Herzenberg
Journal:  Nature       Date:  1980-06-26       Impact factor: 49.962

5.  Regulatory effect and mechanism of gastrin and its antagonists on colorectal carcinoma.

Authors:  Shuang-Wu He; Kang-Qiang Shen; Yu-Jun He; Bin Xie; Yan-Ming Zhao
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

Review 6.  The pivotal role of John S. Edkins in the discovery of gastrin.

Authors:  I M Modlin; M Kidd; I N Marks; L H Tang
Journal:  World J Surg       Date:  1997-02       Impact factor: 3.352

Review 7.  Review article: gastrin and colorectal cancer.

Authors:  A M Smith; S A Watson
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

Review 8.  Gastrin as a growth factor in the gastrointestinal tract.

Authors:  T J Koh; D Chen
Journal:  Regul Pept       Date:  2000-09-25

9.  Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

Authors:  P Costantino; S Viti; A Podda; M A Velmonte; L Nencioni; R Rappuoli
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

10.  A phase II study of G17DT in gastric carcinoma.

Authors:  A D Gilliam; S A Watson; M Henwood; A J McKenzie; J E Humphreys; J Elder; S Y Iftikhar; N Welch; J Fielding; P Broome; D Michaeli
Journal:  Eur J Surg Oncol       Date:  2004-06       Impact factor: 4.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.